Poor data is hindering machine learning, US drug development, study says: A lack of proper data is hurting the use of machine learning to develop drugs, which could put U.S. drugmakers at a competitive disadvantage compared to other countries, according to a report from the U.S. Government Accountability Office and the National Academy of Medicine.